Suzhou Ribo Life Science Co., Ltd. and Insilico Medicine have entered into a strategic collaboration to integrate artificial intelligence platforms into small interfering RNA (siRNA) drug development across discovery and clinical stages.

• The collaboration covers target discovery, drug design, molecular optimisation, and clinical translation for siRNA-based therapeutics.
• It combines Ribo’s algorithm-driven siRNA sequence design tools with Insilico Medicine’s Pharma.AI platform and automated biology systems.
• Both companies are listed on the Hong Kong Stock Exchange, with Insilico Medicine listed on 30 December 2025 and Ribo on 9 January 2026.

This summary is based on a press release issued by Suzhou Ribo Life Science Co., Ltd. and distributed via PR Newswire.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.